# HeartPhone Cancer Survivors Trial 2019

> **NCT03953326** · PHASE1,PHASE2 · TERMINATED · sponsor: **Penn State University** · enrollment: 2 (actual)

## Conditions studied

- Breast Cancer
- Leukemia
- Lymphoma

## Interventions

- **BEHAVIORAL:** HeartPhone app
- **DRUG:** Acetylcholine
- **DRUG:** Sodium Nitroprusside
- **DRUG:** L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester

## Key facts

- **NCT ID:** NCT03953326
- **Lead sponsor:** Penn State University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-23
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Futility in recruitment
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03953326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03953326, "HeartPhone Cancer Survivors Trial 2019". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT03953326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*